A comparison of the efficacy beyond 48 hours of insulin aspart (Novolog) and lispro (Humalog) in insulin pumps

Trial Profile

A comparison of the efficacy beyond 48 hours of insulin aspart (Novolog) and lispro (Humalog) in insulin pumps

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2011

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin lispro (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2010 Status changed from active, no longer recruiting to completed.
    • 01 Apr 2010 Results published in the Journal of Diabetes and its Complications
    • 01 Apr 2010 Status change from active, no longer recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top